[A clinical study in the treatment of acute bacterial infections with fleroxacin].
The purpose of this clinical trial is to evaluate the efficacy and safety of fleroxacin and to compare with those of lomefloxacin. A randomized controlled study was carried out to treat sixty patients with urinary tract and respiratory tract bacterial infections, thirty in each group with one of the two drugs, and fifty cases were treated with fleroxacin in an open trial. Altogether there were one hundred and ten cases. Both fleroxacin and lomefloxacin were given orally, the dosage was 200 mg every 12 hours or 400 mg every 24 hours for 7-14 days. The clinical efficacy rate was 93.3%; the culturing rate in the fleroxacin group was 83.3%; the bacterial clearance rate was 92.3%, the incidence of adverse reactions was 9.4%, while in the lomefloxacin group they were 90.0%, 80.0%, 87.5% and 6.7% respectively, with no statistically significant difference between the two groups (P > 0.05). In the open and randomized trials, fleroxacin cured eighty cases of bacterial infections, the overall clinical efficacy rate was 90.0%, the culturing rate in the flero-xacin group was 83.8%, the bacterial clearance rate was 88.2% and the incidence of adverse reactions was 9.6%. It is shown that fleroxacin is an antibiotic of broad-spectrum, high efficacy and safety.
Hou
J
J
Institute of Clinical Pharmacology, Beijing Medical University.
Li
J
J
Cui
H
H
D000328:Adult; D000890:Anti-Infective Agents / Q000627:therapeutic use*; D005260:Female; D016576:Fleroxacin / Q000627:therapeutic use*; D024841:Fluoroquinolones; D006801:Humans; D008297:Male; D008875:Middle Aged; D015363:Quinolones / Q000627:therapeutic use; D012141:Respiratory Tract Infections / Q000188:drug therapy*; D014552:Urinary Tract Infections / Q000188:drug therapy*
D000890:Anti-Infective Agents; D024841:Fluoroquinolones; D015363:Quinolones; C053091:lomefloxacin; D016576:Fleroxacin